Tag Archives: Common Drug Review

Requesting Feedback for Patient Input Report Template Changes

Requesting Feedback for Patient Input Report Template ChangesProposed Changes to CADTH’s Template for Patient Group Input to CADTH Common Drug Review and pan-Canadian Oncology Drug Review (Word document from CADTH)

Between September 12th and October 25th, CADTH is collected feedback from patient groups on proposed revisions to their patient input template. To submit feedback, please use the feedback form and email it to feedback@cadth.ca. All feedback will be considered and used to help create the final CADTH template, targeted for use in December 2016.

Noticed Changes to the Patient Input Report Template

  • Word limits for answers;
  • Clear table to report how the patient input was gathered;
  • More directly worded questions wanting concise answers;
  • New questions about patient experiences with the treatment in question;
  • 2 pages of questions about patient group conflicts of interest and funding.

More information about these proposed changes and this request for feedback can be found at Feedback on Proposed Revisions to Patient Input Template for CDR and pCODR.

The Canadian Agency for Drugs and Technologies in Health (CADTH)

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence and recommendations to reimbursement programs, such as BC PharmaCare. Their input helps these programs decide whether or not, or how, to provide reimbursement for health technologies, such as drugs, tests, and surgical devices and procedures. Their reviews are Step 4 in the drug approval process for resources, such as hep C treatments, working towards PharmaCare coverage.

Acknowledged by CADTH

CADTH NewsThe Canadian Agency for Drugs and Technologies in Health (CADTH) acknowledged and thanked the Pacific Hepatitis C Network for being one of 17 patient groups who have contributed five or more patient input submissions to their Common Drug Reviews (CDR).

CADTH Common Drug Reviews, and the patient group input reports that are part of them, are important steps towards getting new treatments more widely available in Canada and BC. They allow patients to have their voices heard in the Canadian drug approval process. They allow patients to explain what it’s like to live with their diseases day-to-day. They allow patients to explain what nobody else can explain.

CADTH’s first Call for Patient Input was issued in May 2010. Three patient groups responded to it. That first review was for Actemra, a treatment for rheumatoid arthritis. It was said that, “The groups provided insight and their unique perspectives into the CADTH Common Drug Review’s (CDR) assessment of Actemra.” Over the years, the insight has continued to be sent in by patient groups and used by CADTH.

Since 2010, CADTH has received 297 patient input submissions from 114 groups for Common Drug Reviews. This patient input has contributed to 142 final recommendations for treatments to be reimbursed, or not, by our publicly funded drug plans.

Thank you to all of you who have contributed to patient input reports submitted by the Pacific Hepatitis C Network. We couldn’t have written the reports without you!

The Canadian Agency for Drugs and Technologies in Health (CADTH)

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence and recommendations to help make informed decisions about the use of health technologies, such as drugs, tests, and surgical devices and procedures.

CADTH has brief but interesting videos about itself and patient input submissions posted on YouTube.

CADTH's list of the 17 patient groups that have contributed five or more patient group input submissions
The above is a snapshot of CADTH’s list of the 17 patient groups that have contributed five or more patient group input submissions to Common Drug Reviews over the past five years. The complete article, Five Years of Patient Engagement, can be found online.

Did you spot yesterday’s typo?

sq_drugsBlog Entry Correction

Yesterday’s blog post about Harvoni passing its Common Drug Review this week stated that one of the Canadian Drug Expert Committee’s recommendations was that liver fibrosis should be “stage 2 or lower“. The post should have read “Liver fibrosis stage ≥ 2” or “Liver fibrosis stage 2 or higher.

I apologize for the typo. I may have been a wee  excited about the Harvoni news.

Harvoni Passed Common Drug Review

ledipasvir, sofosbuvir, HarvoniHarvoni, created by Gilead Sciences, passed its Common Drug Review this week with the Canadian Drug Expert Committee (CDEC)’s Final Recommendation. The CDEC’s Final Recommendation advocates that Harvoni, ledipasvir/sofosbuvir, be listed for the treatment of chronic hepatitis C virus (CHC) genotype 1 infection in adults. It recommended 3 conditions for this.

The 3 conditions recommended by the Canadian Drug Expert Committee were:

  • Liver fibrosis be at stage 2 or higher
  • Treatment should be initiated by physicians experienced with treating chronic hep C
  • A substantial reduction in price

Reasons for the Recommendations were:

The CDEC’s report also covered such information as the treatment’s background, efficacy, side effects, and cost and cost-effectiveness.

The website for BC’s PharmaCare now lists Harvoni’s Drug Review Start Date as March 18th, 2015.

Footnote:

When I read the report, I found an interesting note under “Other Discussion Points”. It said that although the ION trials didn’t look at patients coinfected with HCV and HIV, the committee did and cited that ERADICATE, a recently completed trial, demonstrated similar SVR12 rates (98%) in patients coinfected with HCV and HIV to those reported in the three ION trials.